Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074196 | 0.79 | IMPDH2 (0.41) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL10505940 | 0.71 | GABRA1 (0.35) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL3886120 | 0.69 | IMPDH2 (0.71) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL127256 | 0.68 | ALDH1A1 (0.40) | IMPDH2IMPDH1TDP1MAPTHPGD | |
| SCHEMBL3879220 | 0.64 | IMPDH2 (0.57) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL9651757 | 0.64 | HTR2C (0.56) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL29450053 | 0.64 | HTR2C (0.56) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL1490130 | 0.62 | IMPDH2 (0.55) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL4281644 | 0.62 | IMPDH2 (0.41) | IMPDH2IMPDH1RECQLTDP1MAPT | |
| SCHEMBL6161416 | 0.61 | FFAR1 (0.41) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110713588-B | Hardmask composition, hardmask layer and method of forming pattern | 三星SDI株式会社 | 2022-08-09 | — | — | CN | claimed |
| CN-110713588-A | Hardmask composition, hardmask layer and method of forming pattern | 三星SDI株式会社 | 2020-01-21 | — | — | CN | claimed |
| US-7186744-B2 | Prostamides for the treatment of glaucoma and related diseases | ALLERGAN, INC. (US) | 2007-03-06 | — | — | US | claimed |
| CN-116648765-A | Ionic polymers and copolymers | 十二益公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116635963-A | Semi-interpenetrating and cross-linked polymer and film thereof | 十二益公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-110713588-B | Hardmask composition, hardmask layer and method of forming pattern | 三星SDI株式会社 | 2022-08-09 | — | — | CN | disclosed |
| CN-110713588-A | Hardmask composition, hardmask layer and method of forming pattern | 三星SDI株式会社 | 2020-01-21 | — | — | CN | disclosed |
| EP-1341766-B1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| EP-1341766-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| US-6518293-B2 | Inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. | HOFFMANN-LA ROCHE INC. | 2003-02-11 | — | — | US | disclosed |
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002042279-A1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107272-A1 | Anti-HIV imidazolone derivatives | EIF2AK2, IMPDH1, POLR2E | IMPDH2 7/4885IMPDH1 2/4885RECQL 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.